GSK’s new PhI­II da­ta sup­port bid for wider en­dome­tri­al can­cer la­bel for Jem­per­li

GSK’s PD-1 an­ti­body Jem­per­li has hit the bench­mark in a late-stage en­dome­tri­al can­cer test, paving the way for a po­ten­tial la­bel ex­pan­sion be­yond its cur­rent in­di­ca­tion.

The FDA green­lit Jem­per­li plus chemother­a­py for front­line mis­match re­pair de­fi­cient (dMMR) and mi­crosatel­lite in­sta­bil­i­ty-high (MSI-H) ad­vanced or re­cur­rent en­dome­tri­al can­cer in Ju­ly 2023, fol­low­ing a pri­or ap­proval in pre­treat­ed dis­ease. But the new da­ta show Jem­per­li reg­i­mens could ben­e­fit a broad­er set of pa­tients, GSK said in a Sat­ur­day re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.